Cedars-Sinai Medical Center - UCLA School of Medicine

Samuel Oschin Comprehensive Cancer Institute

Los Angeles, CA

Sorting 2 by

Accepting patients

LYT-200

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
Learn more
  • Monoclonal Antibody
  • Galectin-9 Protein
  • Phase 1

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Learn more
  • Genetic Sequencing
  • Phase 2